安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Vernalis
Vernalis has collaborated with a wide range of partners to enable some of the most challenging therapeutic targets Present and past collaborators include Servier, Pierre Fabre, Genentech and Lundbeck
- About us - Vernalis
“We collaborate with Vernalis on an integrated drug discovery project where Vernalis has delivered remarkable results against an historically “undruggable” target The team possesses a powerful blend of creativity and scientific rigor and have been superb colleagues to work with on a personal level
- News Publications - Vernalis
Find Us Vernalis (R D) Limited Granta Park Great Abington Cambridge CB21 6GB United Kingdom Follow Us Vernalis is a member of the HitGen group of companies
- Our History - Vernalis
The new three-year research collaboration combined Vernalis’ strengths in structure and biophysics-based methods with oncology expertise at Servier, to enable drug discovery related to several undisclosed proteins identified as potential therapeutic targets
- Chemistry - vernalis. com
Lee Walmsley has been with Vernalis since 2001 and, prior to that, was with Roche for 9 years Lee has led successful drug discovery projects in collaboration with our partners based in Europe, USA and Japan He is a champion of bringing new methodologies to our chemistry group
- Research Case Studies - vernalis. com
For further information about partnering with Vernalis, or to find out more about our capabilities or career opportunities
- Biophysics and Structural Biology - vernalis. com
Dr Lisa Baker joined Vernalis Research over twenty years ago, having previously completed a degree and PhD in Biophysics and a postdoctoral position in the York Structural Biology Laboratory She is the Senior Team Leader of the Protein Crystallography NMR groups
- Pierre Fabre Laboratories and Vernalis announce a drug discovery . . .
Castres, France and Cambridge UK, 25 September 2023 – Pierre Fabre Laboratories and Vernalis (R D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc , are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets
|
|
|